⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CELC News
Celcuity Inc. Common Stock
CD22 Targeted Therapies Market Research Report 2025-2026: Opportunities Lie in Developing Precise CD22 Targeted Therapies for Blood Cancers, with Over 20 Ongoing Clinical Trials
globenewswire.com
PFE
AZN
UMBF
CELC
REGN
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
globenewswire.com
ONCY
SLS
CELC
RNXT
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report USA - English India - English
prnewswire.com
CLVT
LLY
GSK
JNJ
SNY
CELC
CRBP
BMY
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
globenewswire.com
CELC
CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting
newsfilecorp.com
CELC
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
JAZZ
PRE
ABBV
AMGN
GILD
BMY
AZN
INCY
PFE
CELC
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
globenewswire.com
CELC
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference
globenewswire.com
CELC
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
globenewswire.com
CELC
Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
CELC